Efficacy of phytosomal curcumin among patients with non-alcoholic fatty liver disease.

Abstract

Scientists proposed that curcumin could be used for treatment of non-alcoholic fatty liver disease (NAFLD). In this article, we aimed to identify the effect of curcumin on NAFLD improvement. Fifty patients with NAFLD, were divided into two groups in this randomized, double-blind, and controlled clinical trial. Patients in the curcumin group received 250mg/day of phytosomal curcumin, while those in the control group received 250mg/day of placebo for duration of eight weeks. Anthropometric measurements and fasting blood samples were taken once at the baseline and once at the end of the study. Analysis was performed on 45 patients (curcumin group n=22, placebo group n=22). According to between groups analysis, curcumin significantly reduced the carboxymethyl lisine (CML) (148±108ng/mL vs 197±101ng/mL, P=0.04), 8-hydroxy-2' -deoxyguanosine (8-OHdG) (46.9±31.1ng/mL vs 52.1±43.1ng/mL P=0.03), liver enzymes (P<0.001), weight (P<0.001), waist circumference (P<0.001), body fat percent (P < 0.01), and body mass index (BMI) (P < 0.01) in comparison with placebo. However, curcumin supplementation compared to placebo did not reduce soluble receptors for advanced glycation end products (sRAGE), hip circumference, waist/hip, and fat free mass by the end of the study. Our study indicated that phytosamal curcumin might be able to reduce the NAFLD progress by reducing the anthropometric measures, AGEs, and DNA damage. However, we need more studies with longer intervention duration, and larger sample size.